Despite the success of tyrosine kinase-based cancer therapeutics, for most solid tumors the tyrosine kinases that drive disease remain unknown, limiting our ability to identify drug targets and predict response. Here we present the first large-scale survey of tyrosine kinase activity in lung cancer. Using a phosphoproteomic approach, we characterize tyrosine kinase signaling across 41 non-small cell lung cancer (NSCLC) cell lines and over 150 NSCLC tumors. Profiles of phosphotyrosine signaling are generated and analyzed to identify known oncogenic kinases such as EGFR and c-Met as well as novel ALK and ROS fusion proteins. Other activated tyrosine kinases such as PDGFRa and DDR1 not previously implicated in the genesis of NSCLC are also identified. By focusing on activated cell circuitry, the approach outlined here provides insight into cancer biology not available at the chromosomal and transcriptional levels and can be applied broadly across all human cancers.
INTRODUCTION
Lung cancer is the leading cause of cancer mortality in the world today. Despite decades of intensive analysis, the majority of molecular defects that play a causal role in the development of lung cancer remain unknown. Two oncogenes important in lung cancer are K-RAS and EGFR, mutated in 15% and 10% of NSCLC patients. Large-scale DNA sequencing efforts have identified mutations in PI3KCA, ERBB2, and B-RAF that together represent another 5% of NSCLC patients (Greenman et al., 2007; Thomas et al., 2007) . Analysis of recurrent chromosomal aberrations including amplification and deletion using CGH and SNP arrays promises to identify many additional genes altered in cancer Neve et al., 2006) . However, genetic approaches suffer from the difficulty of identifying a small number of causal changes within a sea of changes associated with genome instability. As a result, strategies and methods are needed to focus analysis on the key lesions driving disease.
One such strategy involves analysis of the cellular signaling pathways corrupted in cancer (Vogelstein and Kinzler, 2004) . Although signaling pathways controlling cell growth and differentiation are almost always altered, the tools to survey complex signaling networks and identify the alterations that lead to cancer have not been available. Signaling via tyrosine kinases is often deregulated in cancer as these enzymes mediate most growth and survival signaling in multicellular organisms (Blume-Jensen and Hunter, 2001) . The recent success of selective tyrosine kinase inhibitors depends upon the identification of tumors that are driven by activated kinases and are therefore dependent upon the targeted kinase for their survival and clinical benefit (Dowell and Minna, 2005; Weinstein, 2002) . Collectively, these observations emphasize the need for better methods to identify and understand the role of activated tyrosine kinases in the initiation and progression of disease.
Recent advances in methods to profile phosphotyrosine signaling have enabled analysis of known model systems (Rush et al., 2005; Wolf-Yadlin et al., 2006) and several hematological cancers Walters et al., 2006) . Here we broadly survey tyrosine kinase signaling across many lung cancer cell lines and solid tumors in order to classify them based upon aberrant tyrosine kinase signaling. Because tyrosine kinases are themselves phosphorylated on tyrosine in proportion to their activity, this study represents the first large-scale analysis of tyrosine kinase activity in lung cancer with the identification of over 50 different tyrosine kinases and over 2500 downstream substrates. We analyze this data using hierarchal clustering and by ranking tyrosine kinase phosphorylation/activity to identify candidate oncogenes. Using this approach we identify known tyrosine kinases such as EGFR and c-Met as well as novel oncogenic tyrosine kinases not previously known to play a role in lung cancer. Upon further biochemical, functional, and clinical analysis we identify new subtypes of NSCLC that express activated forms of ALK, ROS, and PDGFRa.
RESULTS

Phosphotyrosine Profiles of NSCLC Tumors and Cell Lines
Immunohistochemistry (IHC) and a phosphotyrosine-specific antibody were used to screen 96 paraffin-embedded, formalin-fixed tissue samples from NSCLC patients (Figure 1A) . Approximately 30% of tumors showed high levels of phosphotyrosine expression. This group of patient (C) Immunoaffinity profiling method. Cells or tissues are lysed in urea buffer and digested with protease. The resulting peptides are immunoaffinity purified using immobilized phosphotyrosine-specific antibody (P-Tyr-100) and analyzed by LC-MS/MS as described in Experimental Procedures. Because larger liquid chromatography peaks are sampled more times than are smaller peaks, the number of observed spectra assigned to a particular protein is a semiquantitative measure of the abundance of that protein. samples also showed high levels of receptor tyrosine kinase (RTK) expression, suggesting that RTK activity may play a role in the genesis of these lung tumors. Immunoblotting of 41 NSCLC cell lines with a phosphotyrosinespecific antibody also showed heterogeneous reactivity especially in the molecular weight range characteristic of receptor tyrosine kinases ( Figure 1B) .
To further characterize tyrosine kinase activity in NSCLC cell lines and solid tumors we used an immunoaffinity phosphoproteomic approach. Because phosphotyrosine represents less than 1% of the cellular phosphoproteome as determined by tandem mass spectrometry (MS/MS) (Olsen et al., 2006) and is difficult to analyze by conventional methods, we used immunoaffinity purification with a phosphotyrosine antibody to enrich for phosphotyrosine-containing peptides prior to analysis by tandem mass spectrometry (Rush et al., 2005) . All tumors were identified as NSCLC based upon standard pathology. Only tumors with greater than 50% of cancer cells were included in the analysis. NSCLC cell lines were grown overnight in low serum before analysis to reduce background phosphorylation resulting from culture conditions.
Although current technology limitations may somewhat bias our data sets, for example, tryptic phosphopeptides that are either too small or too large to be identified by MS/MS will not be detected, we nevertheless simultaneously measured the phosphorylation status of a large number of sites (ranging between 150 and 1200 nonredundant sites/cell line or tumor). Tables S1 and S2 (available online) show selected phosphotyrosine profiles from a total of 41 NSCLC cell lines and 150 NSCLC tumors. 4551 sites of tyrosine phosphorylation were identified on greater than 2700 different proteins, dramatically extending our knowledge of tyrosine kinase signaling in NSCLC. When these sites were queried against PhosphoSite (www.phosphosite.org), a comprehensive resource of known phosphorylation sites (Hornbeck et al., 2004) , more than 85% appeared novel. These data have been deposited as Supplemental Data on the Cell website and in PhosphoSite and the data sets are freely available via http://www.phosphosite.org/papers/rikova01.html.
NSCLC Tyrosine Phosphorylation
As an initial step to screen for phosphotyrosine signaling abnormalities and to compare NSCLC proteins based upon phosphopeptide data sets, we adopted a semiquantitative approach using the number of phosphopeptide assignments to approximate the amount of phosphopeptide present in the sample. Roughly speaking, the wider the peak eluting from the LC column the more frequently a phosphopeptide is detected by LC MS/MS and hence the more phosphopeptide present in the sample (see Figure 1C ). For example, comparison of phosphopeptide numbers for c-Met with the levels of phosphorylated cMet protein observed by western analysis are in good agreement (Gilchrist et al., 2006; Old et al., 2005; Zybailov et al., 2005 ) (see Figure 1D ). We found this approach preferable to other methods such as parent ion peak height because it allowed us to simplify the analysis by combining all sites on a given protein.
We next compared the distribution of protein tyrosine phosphorylation in NSCLC cell lines and solid tumors based upon protein classification.
As shown in Figure 2A , protein kinases, adhesion proteins, and components of the cytoskeleton are the most highly phosphorylated protein types. When comparing NSCLC cell lines and tumors it is important to note that tumors represent a complex tissue ranging from 50% to 90% cancer cells. The tyrosine kinases, c-Met, EGFR, and EphA2 show the highest levels of receptor tyrosine kinase phosphorylation in cell lines while tumors show high levels of DDR1, EGFR, DDR2, and Eph receptor tyrosine kinase phosphorylation ( Figure 2B ). Fak and Src-family kinases make up the majority of NSCLC nonreceptor tyrosine kinase phosphorylation ( Figure 2C ). Most phosphorylation occurs at the activation loop of these kinases (Table  S2) . Analysis of 266 different phosphorylation sites on over 56 different tyrosine kinases suggests that virtually all sites (with a few exceptions such as the src family C-terminal sites) are positively associated with kinase activity (BlumeJensen and Hunter, 2001; Ullrich and Schlessinger, 1990) ; hence, we assume that tyrosine kinase phosphorylation is a good readout of kinase activity in what follows.
Tyrosine Kinases Activated in NSCLC
A fraction of NSCLC tumors and cell lines exhibit high tyrosine phosphorylation ( Figures 1A and 1B) possibly as a result of activated/overexpressed tyrosine kinases. To identify abnormally activated tyrosine kinases, we subtracted an average signaling profile derived from either the 41 different NSCLC cell lines or the 150 NSCLC tumors to obtain the unsupervised hierarchal clustering results shown in Figures 2E and 3A (see Experimental Procedures). This analysis highlights differences among cell lines and identifies highly phosphorylated (activated) tyrosine kinases (compare Figures 2D and 2E) . Results are consistent with previous reports of activated EGFR (Amann et al., 2005) , ErbB2 (Stephens et al., 2004) , ErbB3 (Engelman et al., 2005) , EphA2 (Kinch et al., 2003) , and c-Met (Ma et al., 2005) receptor tyrosine kinases in NSCLC cell lines. EGFR kinase activity is elevated in 11 cell lines ( Figure 2E ), and among these, five cell lines harbor EGFR-activating mutations. For example, high levels of EGFR phosphopeptides are observed in HCC827 (Amann et al., 2005) and H3255 (Paez et al., 2004; Tracy et al., 2004) , known to express amplified and mutated EGFR. High levels of c-Met and ErbB2 are observed in H1993 and Calu-3 cell lines, respectively, consistent with previous reports (Lutterbach et al., 2007; Ma et al., 2005; Minami et al., 2007) and confirming known receptor tyrosine kinase activity in NSCLC cell lines.
A similar analysis of NSCLC tumors is shown in Figure 3A for all tyrosine kinases and in Figure S1 for all tyrosine kinase phosphorylation sites. Five major groups of tumors are identified using unsupervised Pearson clustering ( Figure 3A) . From left to right are tumors aberrantly expressing the following: only one or two highly active tyrosine kinases (group 1), tumors expressing active Fak together with many different Src, Abl, and receptor tyrosine kinases (group 2), tumors expressing activated DDR1 together with src and abl kinases (group 3), tumors expressing Src kinases with RTKs such as EGFR (group 4), and tumors expressing predominately src and Abl tyrosine kinases (group 5).
Tyrosine Kinase Substrates
We next separately analyzed phosphorylated substrates (excluding tyrosine and Ser/Thr kinases) from each group (B) Distribution of spectral counts among receptor tyrosine kinases (RTK). The total numbers of observed spectra assigned to each RTK over all of the cell lines (top) or the tumors (bottom) are represented as fractions of the total RTK spectra observed. (C) Distribution of spectral counts among nonreceptor tyrosine kinases. The total numbers of observed spectra assigned to each TK (nonreceptor) over all of the cell lines (top) or the tumors (bottom) are represented as fractions of the total TK (nonreceptor) spectra observed. (D and E) Phosphorylation of tyrosine kinases in lung cancer cell lines. The total number of observed spectra assigned to each TK in each cell line was used as the basis for clustering using the Pearson correlation distance metric and average linkage. In (D), no normalization has been applied; in (E), each value in a row has had the row average subtracted.
Figure 3. Phosphorylated Tyrosine Kinases and Substrates in NSCLC Patients
(A) Clustering of tumors by tyrosine kinase phosphorylation. Spectral counts for tyrosine kinases in patient tumors were normalized to the count for GSK3b and then clustered as described in Figure 2E . Clustering produced five groups of tumors with different sets of tyrosine kinases predominating. (B-D) Phosphorylation of selected nonkinase proteins in different tumor groups. Tumor samples were divided into the groups defined by the clustering in (A), and spectral counts were normalized to the count for GSK3b. After all kinases were removed from the protein set, the data were clustered as in Figure 2E and the top 30 proteins displayed. The tumors used in (B) were from group 1 in (A), those in (C) from group 2, and those in (D) from group 4. and identified the 30 most informative substrates (from over 2500 phosphorylated proteins) for groups 1, 2, and 4 ( Figures 3B-3D ). Different groups have different active kinases and different phosphorylated substrates. Group 2 tumors, with many active tyrosine kinases, show higher levels of downstream phosphorylation than group 1 tumors. For example, group 2 tumors show phosphorylation of proteins involved in motility and cytoskeleton dynamics as well as cell-surface receptors and glycolytic enzymes. Overall, group 1 tumors express lower levels of substrate phosphorylation that fall into several subgroups showing high SHP-1, IRS-1/2, and PI3KR1/2. Group 4 tumors show phosphorylation of different substrates including PTEN and histones.
In general, high phosphotyrosine IHC staining is observed for group 2 tumors, consistent with MS/MS results (see Table S4 ). As shown in Table S4 , we found no striking correlations of hierarchal clustering groups with available patient clinical data and tumor pathology. We also compared tumor protein tyrosine phosphorylation to 48 adjacent lung tissue samples using t test comparison ( Figure S2 ). This analysis identifies significant signaling differences between tumor and normal tissue, including many cytoskeleton and signaling proteins, and provides a rich resource for future followup studies.
Ranking Activated Tyrosine Kinases A fraction of cell lines and tumors express multiple activated tyrosine kinases (see group 2 tumors), complicating the identification of ''driver'' kinase(s) (causally related to disease pathogenesis) from other activated kinases functioning in downstream networks. In addition, hierarchical clustering was not useful in grouping tumors with high EGFR phosphorylation (see Figure 3A) . We instead developed an approach to identify candidate driver tyrosine kinases based upon identifying unusually high levels of tyrosine kinase activity in a subgroup of patients. We summed total phosphorylation for each kinase across either Figure 2E or Figure 3A and divided by the number of cell lines or patients showing above average phosporylation. Table 1 shows the most highly phosphorylated receptor tyrosine kinases ranked by average phosphorylation/ patient or cell line. This analysis identifies unusually high tyrosine kinase phosphorylation in subsets of cell lines or patients and serves to highlight and rank kinases for further followup analysis. Of the top 20 RTKs, 15 are identified in both cell lines and tumors. Of the top 10, Met, ALK, ROS, PDGFRa, DDR1, and EGFR are found in both cell lines and tumors (Table 1) .
We next applied a ranking process to identify candidate disease drivers by ranking kinases based upon total phosphorylation. Among cell lines with the highest EGFR rank, we find that EGFR is often the most highly phosphorylated tyrosine kinase, in others it is among the top 2 or 3 kinases (Table S3 ). All 5 cell lines carrying known EGFR-activating mutations and cell lines carrying known EGFR genomic amplifications are found among the cell lines with highest EGFR rank (see Table S3 ).
We carried out a similar analysis of NSCLC tumor samples using phosphorylation rank to identify tumors showing activated EGFR (Table 2) . NSCLC tumors in this study are all stage 1 or 2 and consist of 74% males, 52% smokers, and 30% adenocarcinoma. Among the 18 tumors with highest EGFR rank, 16 gave readable EGFR kinase domain DNA sequence (Table 2) ; of these, 9/16 tumors show kinase domain-activating mutations with 8/8 adenocarcinomas and 5/5 female nonsmokers showing EGFR-activating mutations, consistent with previous reports of enrichment for female nonsmokers and adenocarcinoma (Lynch et al., 2004; Pao et al., 2004) (Table 2) .
Having demonstrated that tumors with EGFR-activating mutations can be identified by EGFR phosphorylation rank, we used the same approach to identify new candidate driver tyrosine kinases. As shown in Table 1 , Met, ALK, ROS, PDGFRa, DDR1, and EGFR are found in both cell lines and tumors. C-Met was found highly phosphorylated in one patient sample (Table 2) , suggesting amplification as shown for H1993 cells where c-Met is a known driver (Lutterbach et al., 2007) . In contrast to EGFR and c-Met, the kinases ALK, ROS, PDGFRa, and DDR1 have few literature connections to lung cancer. Because cell line models are critical to further testing the role of activated kinases in driving disease, we carefully examined the expression of these candidates in NSCLC cell lines. Protein expression of ROS, ALK, and PDGFRa appeared to be highly upregulated in at least one NSCLC cell line ( Figures S3A, S3B , and S4A). Although DDR1 is active in many tumors (Ford et al., 2007) and is a strong candidate for followup analysis, only H1993 cells express phosphorylated DDR1, and these cells are known to be driven by cMet. Lack of a good DDR1 cell line model shifted our focus to ALK, c-ROS, and PDGFRa where MS/MS data identified corresponding NSCLC cell line models. Tables 2, S1 , and S2 show cell lines and tumors expressing the highest levels of ALK, c-ROS, c-Met, and PDGFRa phosphorylation. As seen for EGFR, these RTKs are often but not always the most highly phosphorylated tyrosine kinase ( Table 2 ), suggesting that they may play a role in driving disease. We also ranked all phosphorylated proteins for cell lines and selected tumors expressing ALK (Figure 3E ), c-ROS ( Figure 3F ), and PDGFRa ( Figure 3G ). Among the most highly phosphorylated substrates, many are shared between cell lines and tumors and may participate in downstream oncogenic signaling (see arrows Figures 3E-3G ). See Table S1 for a complete list of all phosphopeptides found in HCC78, H2228, and H1703 cell lines and six 
ALK and ROS Fusion Proteins in NSCLC Cell Lines and Tumors
High-level phosphorylation of ALK was observed in the group of patients in the upper left corner of Figure 3A , cell line H2228 ( Figures 2E and 4A and Table 1 ) and ROS in one tumor sample and HCC78 cell line ( Figure 4B and Table 1 ). Phosphorylation rank place ALK and ROS near or at the top in these samples (Tables 1 and S3 ). Protein expression of ALK and ROS was restricted among the NSCLC cell lines and exhibited a smaller than predicted molecular weight ( Figures S3A and S3B) . We carried out RT-PCR and DNA sequencing to investigate the expressed RNA transcripts. 5 0 RACE analysis of RNA transcripts derived from H2228 cells and three different tumor samples demonstrated fusion of ALK to EML4, a microtubule-associated protein (see Figure 4C) . A short N-terminal region of EML4 is fused to the kinase domain of ALK at the precise point of fusion observed in other previously characterized ALK fusions ( Figure 4C ), such as the NPM-ALK (Morris et al., 1994) . ALK was also found fused to TFG (Hernandez et al., 1999) in one tumor sample ( Figure 4D ). This fusion is the same as the short form of TFG-ALK previously observed (Hernandez et al., 2002) . In both EML4 and TFG fusions, a coiled-coil domain is fused to the kinase domain of ALK, likely conferring dimerization/oligomerization and constitutive kinase activity.
Similar analysis of HCC78 cells demonstrates fusion of ROS to the transmembrane solute carrier protein SLC34A2. The N-terminal region of SLC34A2, ending just after the first transmembrane region, is fused N-terminal to the transmembrane region of ROS producing a truncated fusion protein with two transmembrane domains. Two forms of this fusion protein were observed in HCC78 cells that likely represent different splicing products produced from the same translocation event (see Figure 4E) . A second ROS fusion was identified in the c-ROS-positive NSCLC tumor. As shown in Figure 4F c-ROS is fused to the N-terminal half of CD74, a type II transmembrane protein with high affinity for the MIF immune cytokine (Leng et al., 2003) . The N-terminal region of CD74 is fused to ROS at the precise site of SLC34A2-ROS fusion (see Figure 4E) curiously creating a fusion protein with two transmembrane domains as found in the SLC34A2 fusion. Expression of a tagged SLC34A2-ROS fusion protein in mammalian cells showed constitutive kinase activity that localized to membrane fractions (see Figures S3E and  S3F) . We sequenced the kinase domains of ALK and ROS and found no mutations. Experiments carried out using siRNAs against ALK did not induce cell death in H2228 cells, suggesting survival signaling independent of ALK, such as activating mutations in PI3K (Samuels et al., 2005; Samuels and Velculescu, 2004) or inactivation of PTEN (Mellinghoff et al., 2005) . Similar experiments were carried out using siRNAs against ROS. Two different siRNAs against ROS were effective in reducing ROS protein expression and inducing cell death in HCC78 cells ( Figures S3C and S3D) , demonstrating a strict dependence upon ROS signaling for HCC78 cell survival.
Analysis of the most highly phosphorylated substrates in ALK-expressing cell line and tumor samples ( Figure 3E ) identified candidate downstream signaling molecules such as SHIP2, IRS-1, and IRS-2 previously shown to be important downstream mediators of ALK signaling in anaplastic large cell lymphoma. In addition, phosphorylation of EML4, the fusion partner, is prominently seen (Figure 3E ). PTPN11 and IRS-2 previously reported to be important downstream effectors of ROS in glioblastoma (Charest et al., 2006) were identified as highly phosphorylated in c-ROS-expressing samples ( Figure 3F ).
We prepared FISH break-apart probes to either side of the ALK or ROS locus and identified translocations in both c-ROS-expressing cell lines and tumors ( Figure S3H ). As ALK and EML4 are located on the same arm of chromosome 2, deletion of the intervening DNA confirmed the expected break-apart pattern ( Figure S3G ). RT-PCR analysis using ALK and EML4 primers from 103 NSCLC tumors analyzed by MS/MS identified 3 positive samples (Table 2) giving a 3% frequency for EML4-ALK; adding in the TGF-ALK sample gives an overall frequency of ALK fusions as 4% in the Chinese population. PDGFRa Activation in NSCLC: Sensitivity to Imatinib PDGFRa was identified as aberrantly activated in one NSCLC cell line, H1703, and eight different tumor samples ( Figure 5A and Table 1 ). H1703 cells also express phosphorylated EGFR and FGFR1 and several other RTKs (Figure 5A ). Protein expression for PDGFRa was confirmed by western blotting ( Figure S4A ). We next investigated sensitivity of H1703 cells to the PDGFR inhibitor Imatinib (Gleevec) and the EGFR inhibitor Gefitinib (Iressa). Phosphorylation of Akt at Ser473 was blocked by Imatinib but not by Gefitinib treatment (Figure 5B ). Imatinib dose-response experiments ( Figure S4B ) indicated almost complete inhibition of PDGFRa and Akt phosphorylation at 100 nM Imatinib with little if any effect on p44/42MAPK phosphorylation.
Cell proliferation MTT assays were carried out to further investigate the sensitivity of 20 NSCLC cell lines to Imatinib (Table S5 ). As shown in Figure 5C , H1703 cells show a sensitivity profile similar to K562 cells that overexpress Bcr-Abl fusion protein (Druker et al., 2001; Mahon et al., 2000) . In contrast, 19 NSCLC cell lines (A549, H1373, H441, and many others negative for PDGFRa expression) were insensitive to Imatinib ( Figure 5C and Table S5 ), correlating drug sensitivity with kinase phosphorylation. Our Imatinib sensitivity profile differs from a previous report that identified PDGFRa expression in A549 cells and showed sensitivity to Imatinib (Zhang et al., 2003) . To examine the effects of Imatinib on apoptosis, H1703 cells were treated with Imatinib and cleavage of PARP and caspase 3 examined by western blotting and flow cytometry, respectively. Imatinib (0.1 mM) significantly increased cleaved caspase 3 and cleaved PARP expression in H1703 cells ( Figures  S4C and S4D) . We next examined the effects of Imatinib in vivo using mouse xenograft models. Nude mice were injected subcutaneously with H1703 cells and tumor formation monitored over a period of several weeks. Upon appearance of the first visible tumors, mice were treated daily with Imatinib (50 mg/kg) or vehicle for a 2 week period. Imatinib-treated mice showed immediate and profound effects on tumor growth, while tumor growth continued in control mice ( Figures 5D and S4F) . Tumor growth was quantified in control and Imatinib-treated animals (Figure 5D ), demonstrating exquisite sensitivity to Imatinib even in the complex tumor environment.
To analyze the effects of Imatinib on phosphotyrosine signaling, H1703 cells were grown in heavy and light amino acid-labeled media, treated with and without Imatinib, and phosphopeptides analyzed by mass spectrometry/SILAC (Everley et al., 2006; Ong et al., 2002) . Table S6 lists selected proteins and phosphorylation sites that changed upon treatment with Imatinib. Treatment of H1703 cells with Imatinib had different effects on different sites of the PDGFRa receptor ( Figure 5E ). Ten sites of tyrosine phosphorylation were observed and three new sites were identified (Tyr613, 926, and 962). Imatinib also suppressed tyrosine phosphorylation of a number of important downstream signaling proteins including phospholipase Cg 1, the regulatory subunit of PI3K, Stat5, and SHP-2 (see Figure 5F and Table S6 ). In addition, Imatinib suppressed tyrosine phosphorylation of proteins regulating the cytoskeleton and actin reorganization and signaling molecules involved in membrane recycling and endocytosis. The cell-surface metalloproteinase Adam 9 (Mazzocca et al., 2005) known to liberate ligands for EGFR and FGFR (Peduto et al., 2005) was found to be highly phosphorylated in H1703 cells. Imatinib also inhibited phosphorylation of the ras effector Rin1 (Hu et al., 2005) and inhibited phosphorylation of SMS2, an enzyme involved in ceramide synthesis (Taguchi et al., 2004 ) (see Table S6 for a complete list). Western analysis confirmed selected SILAC results ( Figure S4E) . A complete list of SI-LAC results is shown in Table S6 for one experiment. This experiment was repeated on three different occasions with similar results.
PDGFRa in NSCLC Tumor Samples
Peptides from five tumors with the highest levels of PDGFR phosphorylation are analyzed in Table 2 . These tumors are found in group 2 ( Figure 3A ) and also express FAK, Abl, DDR1/2, and VEGF1/2 in addition to many other active tyrosine kinases. Similar to H1703 cells, these NSCLC tumors also show highly phosphorylated adhesion and cytoskeleton proteins ( Figure 3G ), suggesting engagement of cell motility pathways. An independent analysis by IHC using a PDGFRa-specific antibody to screen NSCLC tumor samples identified strong PDGFRa staining in 2%-3% of patient samples (see Table S7 and Figure S4G ). Our results also differ from the report (Zhang et al., 2003) that 100% of NSCLC adenocarcinomas express PDGFRa. Amplification at the PDGFRa locus was observed by fluorescence in situ hybridization (FISH) analysis in one of the IHC-positive NSCLC samples ( Figure S4H ).
DISCUSSION
In this study we apply an unbiased and global phosphoproteomic approach to the analysis of signaling defects in lung cancer. The approach generates a deep and expansive view of tyrosine kinase activity and downstream signaling networks. Because these studies represent an early phase in the characterization of tyrosine kinase signaling, most of the thousands of phosphotyrosine sites identified are novel and their positions in cell circuits and roles in regulating cell function have yet to be established. Given these limitations, can we identify activated circuitry associated with NSCLC and trace it to the kinases driving disease? To address this question, we compare phosphotyrosine signaling across many different NSCLC samples to identify and group samples based upon activated tyrosine kinases.
Classifying Tumors by Activated Tyrosine Kinases
As a test, we first attempted to identify NSCLC tumors driven by EGFR-activating mutations. By ranking EGFR tyrosine kinase activity across cell lines and tumors, we found that high EGFR rank dramatically enriched for EGFR-activating mutations. Of 11 cell lines with high rank, 5 contained known EGFR-activating mutations, and of the 16 EGFR tumors from which we obtained sequence information, 8/9 were adenocarcinomas and 9 contained kinase domain-activating mutations. The remaining squamous cell carcinoma (SCC) patients showing high EGFR activity, perhaps with EGFR genomic amplifications, should be further investigated and may represent a group of candidates for EGFRI therapy.
Our finding that roughly half of the high ranking EGFR cell lines and tumors carry EGFR-activating mutations led us to group tumors based upon tyrosine kinase rank, leading to the identification of tumors expressing kinases activated above mean levels. The RTKs (Met, ALK, DDR1, ROS, VEGFR-2, IGF1R, PDGFRa, EGFR, and Axl) and the non-RTKs (FAK, LYN, FYN , HCK, FRK, BRK, and others shown in Figure 3A ) were found to be highly phosphorylated in NSCLC. Their role in the pathogenesis of NSCLC is largely unexplored and deserves further investigation. Recent large-scale cancer sequencing efforts (Greenman et al., 2007; Thomas et al., 2007) have identified mutations in the activation loop of many of these kinases, suggesting roles as disease drivers.
One important observation from our study is that cell lines and tumors often express many different activated kinases (see Figure 3A , group 2) that may participate together in hierarchical networks or independently in separate parallel pathways. A better understanding of these relationships will help identify the best drug targets and predict when multiple inhibitors may be necessary to drive cell death and may also help predict drug resistance. For example, HCC827 cell death induced by EGFR inhibitors (Amann et al., 2005) can be overcome by amplification of coexpressed c-Met (see Table S3 ) and is observed in a fraction of patients that develop resistance to EGFRIs (Engelman et al., 2007) . A similar resistance mechanism has recently been observed for c-Kit-and PDGFRa-driven tumors of the gastrointestinal tract (GIST), where induction of Axl via ''kinase switching'' confers Gleevec resistance in relapsed patients (Mahadevan et al., 2007) . This suggests that kinase switching might be a general problem in drug resistance and knowledge of coexpressed RTKs may help predict drug resistance and more effective combination drug therapies. Finally, our finding that most NSCLC tumors express different combinations of active tyrosine kinases suggests the need for individualized therapies. The rank order of kinase activity may provide important clues as to network relationships, drug sensitivities, and drug resistance and when combined with information about genetic and chromosomal abnormalities will help guide future therapies.
Gene Fusions in Lung Cancer
A recent report (Soda et al., 2007) identified EML4-ALK fusions in 6.7% of Japanese patients consistent with growing evidence for chromosomal translocations in solid tumors (Mitelman et al., 2004) , particularly prostate cancer (Tomlins et al., 2005) . Our MS/MS findings in the Chinese population indicate a lower frequency (6/137 patients positive for ALK) of approximately 4.4%. Of these 6 patients, 3 were shown to have fusions with EML4 at 2 different breakpoints. One patient was shown to have a fusion with TFG and very high ALK phosphorylation (Table 2); for the remaining two patients we lacked sufficient material to identify the fusion partner. ROS was found to be activated by gene rearrangements resulting in novel chimeric fusion proteins: SLC34A2-ROS, CD74-ROS. Although ROS translocation and overexpression have been previously identified in glioblastoma, to the best of our knowledge ROS translocations have not been previously implicated in epithelial tumors (carcinomas) and appear to be the first examples of transmembrane fusion. PDGFRa is activated by kinase domain mutations in mesenchymal tumors of the GIST along with C-Kit but not in other tumors where overexpression and autocrine or paracrine activation of PDGFRa is observed, including in glioblastoma and ovarian tumors. An important next step will be to identify NSCLC patients with ALK-, ROS-, and PDGFR-positive tumors and to determine their sensitivity to selective tyrosine kinase inhibitors such as Imatinib (Gleevec).
Conclusions
The NSCLC tyrosine phosphorylation data sets reported here are a rich resource for further investigation and provide a unique view of tumor biology. The large number of activated kinases identified and the particular combinations active in a given tumor suggest opportunities to therapeutically intervene to block pathway and network activity using multiple inhibitors. We have followed up on only a small fraction of the activated tyrosine kinases identified here, but in each case, we identified new disease mechanisms in a field well studied by other methods. By combining multiple levels of analysis including genetic, epigenetic, and signaling we can begin to understand the formation of solid tumors and how to identify and target their Achilles heel.
EXPERIMENTAL PROCEDURES
A detailed description of the experimental procedures can be found in the Supplemental Data.
Cell Culture, Reagents, Western Blot, and Immunoprecipitation Analysis All cell culture reagents were purchased from Invitrogen. Human NSCLC cell lines were obtained from American Type Culture Collection. ROS and phospho-PDGFRa antibodies were purchased from Santa Cruz, all other antibodies were from Cell Signaling Technology (CST). Western blot and Immunoprecipitation analyses were performed following CST protocols.
Phosphopeptide Immunoprecipitation and Analysis by LC-MS/MS Mass Spectrometry
Phosphopeptide immunoprecipitation from different cell lines was performed as described previously (Rush et al., 2005) using the PhosphoScan Kit (P-Tyr-100) from CST.
Analysis of Phosphorylation Site Data Sets
To assign peptide sequences, we used the hash string-matching algorithm implemented in Biofacet (Gene-IT) to search proteins in PhosphoSite. If the peptide sequence matched multiple proteins, the protein with the first accession number in alphabetical order was chosen as a representative. For example, GASQAGM#TGY*GMPR matches both SM22-alpha (P37802) and TAGLN3 (Q9UI15) and would be assigned to SM22-alpha. For a few peptides, we manually chose the best studied protein of a set to be the representative. In the case of the peptide GEPNVSY*ICSR matching both GSK3a (P49840) and GSK3b (P49841), GSK3b was assigned as the representative.
We counted the number of spectra observed for each peptide sequence in a mass spectrometry run (Liu et al., 2004) . Spectra were subjected to the quality criteria described below (i.e., Supplemental Experimental Procedures, LTQ-FT MS, Sequest searches, and Vista).
To calculate a protein spectrum count, we summed the numbers for all of the peptides assigned to each protein in that run. Hierarchal clustering was carried out using TIGR's MeV program (Saeed et al., 2003) with Pearson Correlation Distance and Average linkage clustering. The number of times a given phosphoprotein was identified (sum of all observed spectra assigned to that protein) was imported into MeV and used to assemble heat maps. A protein with 15 or more phosphopeptides is shown in red.
For each patient sample, each protein's spectral counts were normalized to those for GSK3b, and the average count for that protein over all tumors was subtracted.
Growth Inhibition Assay
Cell growth inhibition assay was performed with CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) according to manufacturer's suggestion.
Immunohistochemical Staining and Fluorescence
In Situ Hybridization IHC and FISH protocols with criteria for scoring are available in Supplemental Data.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures, four figures, and seven tables and can be found with this article online at http://www.cell.com/cgi/content/full/131/6/1190/DC1/.
